3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Melanoma
6
Carcinoma, Renal Cell
6
Neoplasms
5
Neoplasm Metastasis
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Metastatic Castration-Resistant Prostate Cancer
1
Interventions
Ipilimumab
5
pembrolizumab
3
Nivolumab
3
Paclitaxel
2
Oxaliplatin
2
Doxorubicin
2
Capecitabine
2
CTLA-4 Antigen
2
tremelimumab
1
trastuzumab deruxtecan
1
tebentafusp
1
spartalizumab
1
lenvatinib
1
eribulin
1
envafolimab
1
durvalumab
1
Vemurafenib
1
Surgical Procedures, Operative
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
Leucovorin
1
Immunotherapy
1
Fluorouracil
1
Docetaxel
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Diabetes Mellitus, Insulin-Dependent, 12
×
lenvatinib
×
Clear all
NCT04305054
2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
335 enrolled